- TRADE NAME: Xalkori (Pfizer)
- INDICATIONS: Advanced or metastatic non-small cell lung cancer in ALK-positive patients
- CLASS: Anaplastic lymphoma kinase (ALK) inhibitor, MET (mesenchymal-epithelial transition) inhibitor / MET tyrosine kinase inhibitor, Tyrosine kinase inhibitor
- HALF-LIFE: 42 hours
- FDA APPROVAL DATE: 07/14/2022
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Alfentanil, Atazanavir, Carbamazepine, Clarithromycin, Cyclosporine, CYP3A4 inducers, inhibitors or substrates, Dihydroergotamine, Efavirenz, Ergotamine, Fentanyl, Grapefruit Juice, Indinavir, Itraconazole, Ketoconazole, Nefazodone, Nelfinavir, Neratinib, Olaparib, Phenobarbital, Phenytoin, Pimozide, Quinidine, Rifabutin, Rifampin, Ritonavir, Saquinavir, Sirolimus, St John's Wort, Tacrolimus, Telithromycin, Troleandomycin, Voriconazole
- See adverse reactions attributed to class:
Anaplastic lymphoma kinase (ALK) inhibitor
MET (mesenchymal-epithelial transition) inhibitor / MET tyrosine kinase inhibitor
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of crizotinib in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 08/07/2024
